LENSAR® Reports Third Quarter 2026 Financial Results and Provides Business Update
Globe Newswire•10/11/2026•07:00 ET
0
Key Highlights
- ➤Recurring revenue $12.6M, +17% year over year, reached 89% of total revenue
- ➤Procedure volume 52,545, +12% year over year, while total revenue fell 1% to $14.1M
- ➤LENSAR placed 10 ALLY Systems; backlog stood at 12 systems as of September 30
- ➤ALLY installed base reached approximately 225 systems, expanding 22% year over year
- ➤Adjusted EBITDA $1.7M versus $(0.3)M a year earlier; net loss widened to $(4.7)M
Expert Statements
Nick Curtis, President and CEO of LENSAR
“In-line with the expectations we shared in August, our third quarter results reflected the typical summer seasonality during which surgical scheduling and purchasing decisions contribute to a more measured pace of activity, leading to a sequential decline from a very strong second quarter”
Nick Curtis, President and CEO of LENSAR
“Total revenue declined 1% year-over-year due to lower system sales against a robust number of sold systems in the prior year period, which was partially offset by growth in both procedure volume and recurring revenue. We see the year-over-year growth in these two revenue indicators as clear evidence of the increasing strength of our operational foundation, which we plan to continue leveraging to drive sustainable growth over the long-term.”
Nick Curtis, President and CEO of LENSAR
“LENSAR was built on innovation, and that remains a fundamental aspect of how we intend to continue competing and gain further ground in the laser cataract surgery market”
Nick Curtis, President and CEO of LENSAR
“Over the quarter, our ALLY installed base grew to approximately 225 systems, expanding our opportunity to support surgeons and generate recurring revenue through continued growth in procedure volumes. We remain focused on advancing the capabilities and adoption of our technology, deepening relationships with surgeon partners and distributors, and utilizing this growing installed base to drive success.”
Nick Curtis, President and CEO of LENSAR
“While quarterly results may fluctuate due to the timing of system sales and placements, among other factors, our commitment to innovation and disciplined commercial execution remains unchanged.”
10 ALLY Robotic Cataract Laser Systems(®) (“ALLY System”) Placements in Third Quarter 2026; Backlog of 12 ALLY Systems as of September 30, 2026
Third Quarter Recurring Revenue Grew 17% Year Over Year to $12.6 Million
Get started
Create a free account to read the full story.